Breaking

Storms along Gulf Coast may become first named storm of 2026 Atlantic hurricane season Argentina Fans Go to Extreme Lengths to Support World Cup Champions Trump's Endorsement Suffers Rare Defeat in Georgia GOP Governor Primary Supreme Court Asked to Toss Trump Administration's Attempt to Deport 330,000 Haitians Mike Collins Wins GOP Senate Primary Runoff in Georgia, Will Face Jon Ossoff US Government Aids Elon Musk's xAI in Clean Air Act Lawsuit HPE Offers Free VM Essentials Software to Compete with Broadcom's VMware Pricing Algal Bloom Turns Trump's Renovated Reflecting Pool Chartreuse Anthropic Faces Government Ban on Advanced AI Models Amidst Business Growth Amazon's Project Kuiper Faces Launch Bottlenecks Despite Satellite Readiness Storms along Gulf Coast may become first named storm of 2026 Atlantic hurricane season Argentina Fans Go to Extreme Lengths to Support World Cup Champions Trump's Endorsement Suffers Rare Defeat in Georgia GOP Governor Primary Supreme Court Asked to Toss Trump Administration's Attempt to Deport 330,000 Haitians Mike Collins Wins GOP Senate Primary Runoff in Georgia, Will Face Jon Ossoff US Government Aids Elon Musk's xAI in Clean Air Act Lawsuit HPE Offers Free VM Essentials Software to Compete with Broadcom's VMware Pricing Algal Bloom Turns Trump's Renovated Reflecting Pool Chartreuse Anthropic Faces Government Ban on Advanced AI Models Amidst Business Growth Amazon's Project Kuiper Faces Launch Bottlenecks Despite Satellite Readiness

novartis

Steady2 stories1 sourcesLast updated: 4/28/2026

Related Topicslp(a)cholesterol cardiovascular disease heart attack amgen eli lilly pelacarsen olpasiran

Latest Stories

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."

Pharma Bets Big on Lp(a) Cholesterol Drugs With $5.6B Market Potential

Health·4/27/2026AI summary

Pharma Bets Big on Lp(a) Cholesterol Drugs With $5.6B Market Potential

Novartis, Amgen and Eli Lilly are in late-stage trials for drugs targeting Lp(a), a dangerous form of cholesterol affecting one in five people worldwide. Novartis expects Phase 3 results mid-2026 for pelacarsen, with Amgen and Lilly following in 2027 and 2029. The drugs have shown 80%+ Lp(a) reduction but must now prove clinical benefit. If successful, the market could reach $5.6B by 2032, though less than 1% of U.S. adults currently get tested for Lp(a).